CD274 and angiosarcoma: Other angiosarcoma subtypes vulnerable to PD‐1/PD‐L1 inhibition could be identified using tertiary lymphoid structures (TLS) as a potential predictive biomarker28 in an ongoing clinical trial (NCT04095208).